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Purpose/Objective: During the course of their disease, 30-60% of lung 
cancer patients (pts) develop brain metastasis (BM). Despite local 
and/or systemic treatment survival is dismal. Depending on the 
Recursive Partitioning Analysis (RPA) class median survival is 7 months 
for class 1 and 3 months for class 3. In 2011 the Dutch national 
guideline on BM was revised, advising to actively treat pts with more 
than 3 BM both in RPA class 1 and the majority of pts in class 2 with 
Whole Brain Radiotherapy (WBRT). With lacking evidence of benefit, 
pts in RPA class 3 should be strictly treated palliatively. In this 
retrospective study in a large lung cancer patient cohort we evaluate 
the guideline’s use in daily practice. 
Materials and Methods: Data of all lung cancer pts who underwent 
WBRT for BM referred from one of three collaborating hospitals in the 
South of the Netherlands between March 2004 and July 2012 were 
retrospectively analyzed. Details on performance score (according to 
WHO/Karnofsky(KPS)), age, locally controlled disease, extracranial 
metastasis, time from diagnosis of lung cancer to development of BM, 
histology and survival after diagnosis of BM were collected. The RPA 
class was determined using the first four items. 
Results: 292 WBRT pts had NSCLC. Average age (range) was 62.6 years 
(40.5-83.5) , 59.2% was male, 252 (68.3%) had a KPS of ≥ 70. In 215 
(73.6%) pts the primary tumor was not controlled, 116 (39.7%) had 
extra-cranial metastasis, 93 (31.9%) had BM at primary diagnosis. 96 
WBRT pts had SCLC, average age was 62.1 years (44.7-83.5) , 64.0% 
was male, 86 (89.6%) had a KPS of ≥ 70. In 71 (74.0%) pts the primary 
tumor was not controlled, 37 (38.5%) had extracranial metastasis and 
24 (25.0%) had BM at primary diagnosis.  
For NSCLC, 45 (15.4%) of 292 pts were classified as RPA 1, 210 (71.9%) 
as RPA 2, and 37 (12.7%) as RPA 3. For SCLC this was 7 (7.3%), 75 
(78.1%), and 14 (14.6%), respectively. Before the revised guideline 
was implemented in 2011, on average 10.8% of WBRT pts were 
annually classified as RPA 3. In the year after implementing the 
guideline, this was 7.7 % (p=0,353). Median survival for NSCLC RPA 
class 1, 2, and 3 was 6.5 [95% CI = 3.8-9.2]; 3.0 [95% CI =2.3-3.7] and 
1.5 [95% CI = 0.7-2.2] months, respectively. For SCLC this was 9.0 [95% 
CI = 8.0-10.0]; 4.4 [95% CI = 2.9-6.0] and 2.0 [95% CI = 0.2-3.,8] 
months, respectively (see figure 1). 
 
 Figure1: Overall survival analysis. 
 
Conclusions: Although it is not advised that RPA class 3 pts should 
receive WBRT, approximately 13 % of the analyzed WBRT pts were 
classified as RPA 3. Despite the release/implementation of the new 
national guideline in 2011, we did not find a significant difference 
regarding the treatment of RPA class 3 pts thereafter. The survival of 
RPA class 3 pts is poor and in agreement with RTOG validation studies. 
In our view, guidelines should be implemented more precisely. Better 
awareness amongst physicians would prevent some patients from 
being treated unnecessarily. 
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Purpose/Objective: Standard treatment of locally advanced non-small 
cell lung cancer (NSCLC) corresponds to concomitant chemo-
radiotherapy (2 Gy per fraction until 60-66 Gy). A phase I trial was 
initiated in order to analyse toxicity of standard chemoradiotherapy 
(46 Gy, 2 Gy per fraction) with a stereotactic ablative radiotherapy 
(SABR) boost. The aim of the present study was to develop an 
algorithm able to determine biological equivalent dose received by 
every organ at risk and target volume during radiotherapy using two 
different fractionation schedules. 
Materials and Methods: A phase I trial began in our center in 2010 
and analyzes toxicity after chemoradiotherapy (46 Gy with docetaxel 
and cisplatinum, 2 Gy per fraction) and a boost delivered by SABR (3 X 
7 Gy for the first level, 3 X 12 Gy for the last level). Conventional 
treatment dose matrix and stereotactic dose matrix were fused on the 
same CT-scan (used for SABR treatment). Histogram dose volume was 
evaluated by summation of physical dose after biological conversion 
for each voxel by using the linear quadratic-linear model (LQ-L) and 
the α/β ratio of the delinated organ (ARTIVIEW, AQUILAB SAS, 
France). 
Results: With a median follow-up of 21 months (5-26), 14 patients 
(pts) were treated and 12 (85.7%) experienced grade 1-2 toxicities (no 
grade 3-4 toxicities). One patient died of massive hemoptysis 6 
months after treatment, but also after local and metastatic relapse, 
and bevacizumab treatment. The most frequent toxicity was G1-2 
pulmonary alveolitis (8 pts, 57.1%).When considering dose constraints 
used in conventional treatment, post-hoc analysis of matrix-dose 
revealed that bioequivalent cumulative dose were above the usual 
recommended dose in 3 pts for brachial plexus, 6 pts for pulmonary 
arteries, 4 for superior cave veinous, 2 for heart, 3 for bronchial tree, 
8 for bone, and 3 for lung. When comparing biological summation for 
both conventional and SABR treatment, with only conversion for the 
SABR part there was a median difference of -0.35 Gy (-5.1 ;+0.8). 
Patient with hemoptysis had the highest dose delivered to the big 
vessels (141.7 Gy). 
Conclusions: One toxic death was suspected in this trial and 
correlated with the highest dose received to the big vessels but other 
factors could also explain this event. Otherwise a lot of pts received a 
dose over the limit of dose constraint but with up to now, no grade 3-
5 toxicities suggesting that the LQ-L might not well predict toxicities 
when mixing conventional and SABR treatments, and might 
overestimate bioequivalent dose. This has to be confirmed with longer 
follow-up and a larger number of patients. 
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The last decade has shown a tremendous increase in technological 
developments in radiotherapy in which many types of advanced 
technology emerged. These steps forward concerned: 1) Access of RT 
departments to new diagnostic imaging equipment; 2) Installation of 
new treatment modalities allowing dose delivery that are more 
precise, faster or with greater biological effectiveness; 3) Availability 
of numerous QA devices to verify the dose delivery and patient 
position before or during their treatment; 4) Electronic data transfer. 
Not all potential improvements have led to large scale clinical 
implementation. Cost and reimbursement are obvious reasons, but the 
implementation of new treatment modalities depends also on the 
availability of sufficient expertise and manpower in a department.  
 A large number of physical, technical and clinical problems have to 
be solved before advanced technology can be used in an optimal way. 
For instance, combination of diagnostic imaging information may yield 
improved knowledge of the position of target volume and organs at 
risk, while more advanced optimization and dose calculation 
algorithms may allow better target coverage and sparing of organs at 
risk. However, knowing the possibilities and limitations of these 
procedures is a prerequisite for their safe use by the treatment 
planning team; a process in which medical physicists play an essential 
role. Implementation of new treatment modalities such as proton and 
carbon-ion therapy is still far from routine practice and requires 
